Inovio Pharmaceuticals, Inc. — FY2011 Form 10-K
Reporting period: Fiscal year ended December 31, 2011. The filing also provides unaudited fourth-quarter results. Inovio is a clinical-stage biotechnology company developing synthetic DNA vaccines and electroporation delivery systems; it reported no product sales and no approved human-use products.
Financial performance and position
- Revenue: $9.80 million in 2011, up 59% from $6.14 million in 2010. Grants and miscellaneous revenue were $9.23 million; license and milestone revenue was $568,000. NIAID supplied approximately 80% of revenue.
- Operating results: Operating expenses were $31.43 million, including $20.03 million of R&D (up 51%) and $11.99 million of general and administrative expense. Operating loss widened to $21.64 million from $19.22 million. Net loss attributable to Inovio narrowed to $15.25 million from $17.61 million; loss per share was $0.12 versus $0.17.
- Profitability and margins: The company remained substantially loss-making and had no meaningful product gross margin. Operating loss was approximately 2.2 times revenue.
- Cash flow: Operating cash use increased to $19.76 million from $11.94 million. Investing activities used $10.90 million, primarily reflecting investment purchases and maturities. Financing provided $28.01 million, largely from equity offerings.
- Liquidity: Year-end cash and cash equivalents were $17.35 million, with $12.86 million of short-term investments; working capital was $20.9 million. Total assets were $61.11 million and current liabilities were $11.04 million. Management said outside financing would be needed to meet capital requirements into the third quarter of 2013.
- Debt and obligations: The company reported no material long-term debt; its prior line of credit was repaid and terminated in 2010. Operating lease commitments totaled $1.40 million. Accumulated deficit was $210.1 million.
- Fourth quarter: Revenue was $1.63 million versus $2.36 million in Q4 2010. Net loss attributable to Inovio was $5.48 million versus $6.29 million; loss per share was $0.04 versus $0.06.
Changes versus 2010 and unusual items
- Revenue growth was principally driven by NIAID contract revenue, which rose to $7.80 million from $4.06 million, and higher PATH/MVI and university subcontract revenue. R&D spending increased with clinical trial activity, including initiation of the VGX-3100 Phase II and influenza Phase I studies.
- The improvement in reported net loss did not reflect improved operating performance: operating loss increased. A $8.69 million favorable change in warrant fair value materially reduced the 2011 net loss; this was a noncash, valuation-driven item. Inovio also recorded a $2.39 million loss on its VGX International investment and a $587,000 gain on sale of assets.
- Cash declined despite equity financing. January and December 2011 offerings generated approximately $23.0 million and $3.7 million in net proceeds, respectively, and increased common shares outstanding to 134.97 million from 105.04 million. Associated warrants are a source of potential dilution and were recorded as liabilities.
Business outlook, commentary, and risks
- The pipeline included Phase II therapeutic HPV/cervical dysplasia candidate VGX-3100; Phase I programs included avian influenza and several HIV vaccine studies. Prostate cancer and universal influenza programs remained preclinical or earlier stage. Reported immune responses are not evidence of clinical efficacy.
- Inovio expected substantial further operating losses and said it may never achieve profitability. Continued development depends on additional capital, grants, collaborations, and successful clinical and regulatory outcomes; no revenue guidance was provided.
- Key risks include early-stage clinical development, trial failure or delay, regulatory approval and manufacturing hurdles, competition, and dependence on third parties. Revenue concentration is significant: NIAID accounted for 80% and PATH/MVI 8% in 2011; government awards can be renewed, reduced, or terminated.
- Related-party considerations include Inovio’s 16.1% ownership of VGX International, its collaboration and licensing arrangements with VGX, and reliance on VGX’s subsidiary as a DNA-plasmid supplier. The filing also notes $2.7 million of scheduled OncoSec payments for sold assets that were not recorded as a receivable because collection was not reasonably assured.
- The company reported effective disclosure controls and internal control over financial reporting. Ernst & Young issued unqualified opinions on the financial statements and internal controls.
Most important facts for investors to verify
- Cash, short-term investments, quarterly cash burn, and the timing and terms of any financing needed beyond the stated Q3 2013 horizon.
- NIAID contract funding, option-year status, and the extent to which revenue remains concentrated in government and grant sources.
- Clinical-trial enrollment, safety, efficacy endpoints, and actual outcomes for VGX-3100, influenza, and HIV programs; distinguish immunogenicity from demonstrated patient benefit.
- Warrant liability valuation and potential dilution from outstanding warrants, options, and future equity issuance.
- VGX-related supply, collaboration, and related-party economics, as well as collectability of contingent OncoSec payments.